ArticleDrug design, development and therapy2015
A novel glycyrrhetinic acid-modified oxaliplatin liposome for liver-targeting and in vitro/vivo evaluation.
Article in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Targeted Nanocomplex Delivery for Protecting Vascular Integrity and Enhancing Anticancer Effects in Hepatocellular Carcinoma.Small science · 2026Article
- Mapping research hotspots and trends in hepatocellular carcinoma nanomedicine: a bibliometric analysis.Discover oncology · 2025Article
- Recent Advances in Glycyrrhetinic Acid-Functionalized Biomaterials for Liver Cancer-Targeting Therapy.Molecules (Basel, Switzerland) · 2022Review
- The Optimized Delivery of Triterpenes by Liposomal Nanoformulations: Overcoming the Challenges.International journal of molecular sciences · 2022Review
- Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer.International journal of nanomedicine · 2022Review
- Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18β-Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer.Pharmaceutics · 2021Review
- Article
- Research progress on the protective effects of licorice-derived 18β-glycyrrhetinic acid against liver injury.Acta pharmacologica Sinica · 2021Review
- In vitro and in vivo Evaluation of a Novel Estrogen-Targeted PEGylated Oxaliplatin Liposome for Gastric Cancer.International journal of nanomedicine · 2021Article
- A Novel Targeted Therapy System for Cervical Cancer: Co-Delivery System of Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier.International journal of nanomedicine · 2021Article
- Preparation, Characterization, and in vivo Evaluation of NK4-Conjugated Hydroxycamptothecin-Loaded Liposomes.International journal of nanomedicine · 2020Article
- Preparation andDrug delivery · 2019Article
- Development of 11-DGA-3-Molecules (Basel, Switzerland) · 2019Article
- Nanostructured carriers as innovative tools for cancer diagnosis and therapy.APL bioengineering · 2019Review
- Antitumor activities of novel glycyrrhetinic acid-modified curcumin-loaded cationic liposomes in vitro and in H22 tumor-bearing mice.Drug delivery · 2018Article
- Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate.Experimental and therapeutic medicine · 2018Article
- Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.International journal of nanomedicine · 2018Article
- Multifunctional Liposomes for Image-Guided Intratumoral Chemo-Phototherapy.Advanced healthcare materials · 2017Article
- Cancer drug delivery in the nano era: An overview and perspectives (Review).Oncology reports · 2017Review
- A Glycyrrhetinic Acid-Modified Curcumin Supramolecular Hydrogel for liver tumor targeting therapy.Scientific reports · 2017Article
Corrections and comments
- Retraction · 2022-11-18Author Unresponsive · Duplication of/in Image · Paper Mill ·
- Retracted
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, oxaliplatin (OX) liposomes surface-modified with glycyrrhetinic acid (GA) were developed by the film-dispersion method. Their morphology, physical and chemical properties, and in vitro release performance were investigated. The transmission electron microscope (TEM) image showed that most liposomes were spherical particles with similar size and uniform dispersion. Both OX-liposomes and GA-OX-liposomes had an average size of 90 nm. They were negatively charged, with zeta potentials of -20.6 and -21.3 mV, respectively, and the entrapment efficiency values of both were higher than 94%. In vitro data showed that the application of liposomes could prolong the OX release. The relatively high correlation coefficient values obtained from analyzing the amount of drug released versus the square root of time depicted that release followed the Weibull model. No significant changes were observed after the addition of GA to the liposomes. In vivo, the relatively long time to reach the maximum plasma concentration of OX-liposomes suggested a sustained-release profile of liposomes, which was consistent with the results of the in vitro release study. The increased area under the curve and maximum plasma concentration of OX-liposomes and GA-OX-liposomes demonstrated an increased absorption. The drug concentration in tissues indicated that the GA-modified liposomes delivered OX mainly to liver after intravenous administration. In addition, no severe signs, such as appearance of epithelial necrosis or sloughing of epithelial cells, were detected in histology studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.